RNS Number : 0687X
Genedrive PLC
30 December 2021

genedrive plc
("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

Resolutions	Votes For	Vote For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Vote Withheld
1	10,597,308	99.5%	49,547	0.5%	250,964
2	10,450,162	96.6%	371,359	3.4%	76,298
3	10,432,244	96.2%	409,436	3.8%	56,139
4	10,432,244	96.2%	409,436	3.8%	56,139
5	10,341,865	95.5%	491,145	4.5%	64,809
6	10,420,244	96.1%	421,436	3.9%	56,139
7	9,277,547	95.8%	409,436	4.2%	1,210,836
8	10,529,866	97.2%	301,290	2.8%	66,663
9	10,396,600	96.0%	429,809	4.0%	71,410
10	9,237,043	87.3%	1,342,164	12.7%	318,612

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel

finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media Relations & IR) +44 (0)20 7933 8780
or genedrive@walbrookpr.com
Paul McManus +44 (0)7980 541 893

About genedrive plc - www.genedriveplc.com

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently released a test to help in the prevention of hearing loss (Genedrive® MT-RNR1 Kit) caused by specific antibiotics in neonates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBBBDDRBXDGBG